Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:MIRMNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$33.74+0.2%$34.40$21.62▼$39.54$6.41B1.152.43 million shs2.19 million shsMIRMMirum Pharmaceuticals$45.28+2.0%$42.94$23.83▼$54.23$2.24B0.95524,557 shs230,973 shsROIVRoivant Sciences$10.76+0.8%$10.50$8.73▼$13.06$7.68B1.235.58 million shs3.78 million shsRVMDRevolution Medicines$39.44-0.1%$37.48$29.17▼$62.40$7.35B1.111.49 million shs899,044 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+1.20%-6.04%-3.41%+6.65%+16.27%MIRMMirum Pharmaceuticals-1.94%+7.69%+12.12%-12.45%+78.99%ROIVRoivant Sciences-0.84%-4.48%+4.71%+2.11%-5.83%RVMDRevolution Medicines-1.18%+4.83%+8.25%-4.45%+5.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.6707 of 5 stars4.52.00.03.93.43.30.6MIRMMirum Pharmaceuticals4.1599 of 5 stars3.61.00.04.23.52.50.6ROIVRoivant Sciences2.3379 of 5 stars3.51.00.00.04.12.50.0RVMDRevolution Medicines4.2912 of 5 stars4.50.00.04.73.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$57.0969.21% UpsideMIRMMirum Pharmaceuticals 3.17Buy$60.6433.91% UpsideROIVRoivant Sciences 3.00Buy$17.5062.64% UpsideRVMDRevolution Medicines 3.00Buy$67.0870.09% UpsideCurrent Analyst Ratings BreakdownLatest MIRM, ROIV, RVMD, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.004/30/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.004/30/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.004/30/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $72.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$127.42M50.28N/AN/A($7.71) per share-4.38MIRMMirum Pharmaceuticals$379.25M5.91N/AN/A$5.33 per share8.50ROIVRoivant Sciences$122.59M62.63N/AN/A$7.76 per share1.39RVMDRevolution Medicines$742K9,900.82N/AN/A$11.09 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%N/AMIRMMirum Pharmaceuticals-$163.41M-$1.61N/AN/AN/A-31.69%-41.22%-14.81%N/AROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%N/ALatest MIRM, ROIV, RVMD, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/20/2025Q4 2024BBIOBridgeBio Pharma-$1.09-$1.31-$0.22-$1.40$4.04 million$5.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67MIRMMirum Pharmaceuticals1.333.343.15ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%MIRMMirum PharmaceuticalsN/AROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%MIRMMirum Pharmaceuticals14.36%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableMIRMMirum Pharmaceuticals14049.54 million37.03 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableMIRM, ROIV, RVMD, and BBIO HeadlinesRecent News About These CompaniesMaven Securities LTD Acquires Shares of 65,000 Revolution Medicines, Inc. (NASDAQ:RVMD)May 15 at 7:33 AM | marketbeat.comRevolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung CancerMay 14 at 8:00 AM | globenewswire.comIntegral Health Asset Management LLC Purchases 200,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 14 at 6:17 AM | marketbeat.comJ. Goldman & Co LP Invests $1.15 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 14 at 5:59 AM | marketbeat.comJanus Henderson Group PLC Grows Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 14 at 5:56 AM | marketbeat.comEnsign Peak Advisors Inc Buys 265,389 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 14 at 5:26 AM | marketbeat.comGranahan Investment Management LLC Reduces Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)May 13 at 7:14 AM | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 248,326 Revolution Medicines, Inc. (NASDAQ:RVMD)May 13 at 5:05 AM | marketbeat.comResearch Analysts Issue Forecasts for RVMD FY2025 EarningsMay 13 at 3:11 AM | americanbankingnews.comLeerink Partnrs Has Positive Outlook of RVMD FY2025 EarningsMay 13 at 2:56 AM | marketbeat.comWedbush Expects Reduced Earnings for Revolution MedicinesMay 13 at 1:31 AM | marketbeat.comFred Alger Management LLC Sells 392,547 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 12 at 5:35 AM | marketbeat.comAmeriprise Financial Inc. Acquires 141,426 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 12 at 4:15 AM | marketbeat.comFarallon Capital Management LLC Boosts Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 11, 2025 | marketbeat.comAlgert Global LLC Buys 6,925 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 11, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Stake Boosted by Schonfeld Strategic Advisors LLCMay 11, 2025 | marketbeat.comRevolution Medicines' (RVMD) "Buy" Rating Reiterated at Needham & Company LLCMay 11, 2025 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given "Buy" Rating at Needham & Company LLCMay 10, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is DAFNA Capital Management LLC's 3rd Largest PositionMay 10, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Deerfield Management Company L.P. Series C's 7th Largest PositionMay 10, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 6,698 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRM, ROIV, RVMD, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$33.74 +0.08 (+0.24%) As of 04:00 PM EasternBridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Mirum Pharmaceuticals NASDAQ:MIRM$45.28 +0.89 (+2.00%) As of 04:00 PM EasternMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Roivant Sciences NASDAQ:ROIV$10.76 +0.09 (+0.84%) As of 04:00 PM EasternRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$39.44 -0.04 (-0.10%) As of 04:00 PM EasternRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
